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 Kidney function for the non-
nephrologist: an emerging tool 
for predicting mortality risk 
 Stein I.  Hallan 1 
 Estimated glomerular filtration rate (eGFR) and albuminuria are among 
the most important cardiovascular risk factors, but the optimal cutoff for 
predicting mortality may not yet have been agreed upon. Foley  et al. 
analyzed data from the population-based NHANES III study with 
classification tree methodology. They found that an eGFR of 94  ml / min 
per 1.73  m 2 and an albumin – creatinine ratio of 9  mg / g were the optimal 
cutoff values, that is, more  ‘ normal ’ values than are used to define 
chronic kidney disease. 
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 Cardiovascular disease has been a major 
public-health problem for more than 50 
years in the developed world. Enormous 
research eff orts have been undertaken to 
understand cardiovascular diseases, and 
great progress has been made in both pre-
vention and treatment. During the past 20 
years, we have experienced a tremendous 
decline in cardiovascular mortality among 
middle-aged people, and substantial 
improvements in treatment have also been 
achieved in the elderly. 1 
 Discovering major risk factors for car-
diovascular diseases and organizing these 
into risk prediction scores have been 
important in this progress. In the INTER-
HEART study, nine risk factors accounted 
for 90 % of the population attributable 
risk for incident myocardial infarctions. 2 
However, this might be too optimistic, 
and, at least in clinical practice, we are 
not able to predict 90 % of all future car-
diovascular events. Th e  ‘ number needed 
to treat ’ to prevent one cardiovascular 
event is still oft en estimated to be around 
100. 3 Th is rather high number is proba-
bly due to both lack of treatment eff ec-
tiveness and suboptimal risk stratifi cation 
of the patients, and, especially in the eld-
erly, the latter could be a substantial 
problem. Both the Framingham risk 
equation and the Systematic Coronary 
Risk Evaluation (SCORE) equation were 
developed for subjects younger than 70 
years old. Likewise, the predictive value 
of major risk factors such as hyperten-
sion and dyslipidemia is reduced in the 
elderly. 4 Th e reasons for this  ‘ reversed 
epidemiology ’ are several, but survival 
bias is probably one of the most impor-
tant. To improve risk stratifi cation testing 
for subclinical atherosclerosis could be 
one possible way forward, especially in 
the elderly. Measurement of carotid 
intima – media thickness and measure-
ment of coronary calcifications with 
ultrasound and computed tomographic 
scanning, respectively, are techniques 
with high diagnostic accuracy but low 
availability. 5 Chronic kidney disease has 
been increasingly suggested as a potential 
 ‘ test ’ for cardiovascular risk prediction, 
as it has high diagnostic accuracy like the 
aforementioned methods, has no side 
eff ects, and is much cheaper. However, 
the optimal use of estimated glomerular 
fi ltration rate (eGFR) and urinary albu-
min excretion is not yet agreed upon. 
 Foley  et al. 6 (this issue) make an inter-
esting contribution to this topic. Using the 
large population-based Th ird National 
Health and Nutrition Examination Survey 
(NHANES III) cohort from the United 
States, they studied how well kidney func-
tion and other risk factors predicted mor-
tality risk, using classifi cation tree analysis. 
Th eir main fi nding is that, for optimal 
prediction of mortality risk, more  ‘ near-
normal ’ cutoff  values for kidney function 
should be used. Th e current 2002 Kidney 
Disease Outcomes Quality Initiative 
(KDOQI) uses an eGFR below 60  ml / min 
per 1.73  m 2 and an albumin – creatinine 
ratio above 30  mg / g for defi nition and risk 
classifi cation of chronic kidney disease 
and its outcomes. Cutoff s for mortality-
risk prediction could, however, be diff er-
ent, and Foley  et al. 6 suggest using an 
eGFR of 94  ml / min per 1.73  m 2 and 
an albumin – creatinine ratio of 9  mg / g as 
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cutoffs. They argue that this gives the 
highest combined sensitivity and specifi -
city for selecting subjects with a high risk 
of dying during the next 9 years. 
Th ese suggestions are based on a combi-
nation of receiver operating characteristic 
(ROC) analysis and classifi cation tree meth-
odology, an exciting but rather unknown 
statistical method in nephro logy journals. 
Such analysis fi rst fi nds the variable that best 
discriminates between the two outcomes, 
that is, the variable with the highest area 
under the ROC curve ( Figure 1 ). Th e opti-
mal cutoff  is then defi ned as the value giving 
the highest combined sensitivity and spe-
cifi city values, that is, the point on the ROC 
curve closest to the upper left  corner. Th e 
study population is then split on the basis of 
this cutoff , and the analysis is then repeated 
in these two groups, omitting the fi rst vari-
able to fi nd the next best variable. In this way 
a classifi cation tree is created, showing which 
variables, in which order, and what cutoff s 
we should use to best discriminate between 
those with a high risk of dying and those 
with a low risk ( Figure 2 ). Th e technique has 
several advantages. It is a simple and straight-
forward method that is easy to understand, 
and the technique is logical, mimicking 
clinical reasoning and screening practice.  It 
is quite diff erent from the traditional Cox 
regression techniques oft en used in medicine 
and can bring up diff erent and interesting 
results. Th e authors should be commended 
for their novel approach to the topic.
 Some aspects of the analyses should, 
however, be discussed. Th e classifi cation 
tree analysis forces all variables to be dichoto-
mized even if there is no statistical or clinical 
reason to do so. Th is leads to loss of statis-
tical power. Neither does the technique 
include a way of measuring uncertainty. It is 
also challenging to interpret some aspects of 
the results. The analyses assign similar 
weight to sensitivity and specifi city. In most 
screening-related settings, a high specifi city 
is given priority over sensitivity to reduce 
the number of false-positive cases. Th ese 
cases will generate additional costs and risks 
through the medical work-up following a 
positive test. On the other hand, there could 
also be settings in which the benefits of 
intervention are so high, and the costs rela-
tively low, that a high sensitivity should be 
prioritized. Such evaluations cannot be done 
intuitively; formal cost – benefi t analyses are 
needed to reach the correct decision. 
 Other studies have also analyzed the 
association between eGFR, albuminuria, 
and mortality. The Hoorn Study was 
among the fi rst to document that small 
increases in serum creatinine could also 
indicate an increased risk. 7 Later studies 
have found that the mortality risk starts to 
increase when eGFR falls below 60  ml / min 
per 1.73  m 2 . However, several of these 
studies were not able to calibrate their 
serum creatinine values to a correct level 
for use with the GFR-estimating equation. 
Th is usually leads to an underestimation 
of GFR, and the optimal eGFR cutoff 
could therefore be higher than 60  ml / min 
per 1.73  m 2 . A further limitation of these 
earlier studies was the lack of a concomi-
tant evaluation of the degree of albuminu-
ria. A few studies have now tested the 
combined eGFR – albuminuria variable. 8 
Both variables were strong, independent 
risk factors, and they also had synergistic 
eff ects (the risk associated with having 
both low eGFR and increased albuminuria 
was higher than the sum of the risk of low 
eGFR alone and the risk of increased albu-
minuria alone). Th e mortality risk started 
to increase at an eGFR of 75  ml / min per 
1.73  m 2 even aft er adjustment for other 
traditional risk factors, including albu-
minuria. Th ese fi ndings have very recently 
been confi rmed in a large collaborative 
meta-analysis including 1.2 million sub-
jects from 21 diff erent cohorts worldwide. 9 
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 Figure 1  |  Underlying analyses. Classification tree analysis, as used by Foley  et al. , 6 starts with receiver operating characteristic (ROC) analysis of all variables 
to find the best variable and optimal cutoff, that is, the highest area under the curve and the point on the ROC curve closest to the upper left corner. In this 
illustration, test A with cutoff 40 is the best test and is used to subdivide the cohort. The remaining variables are then tested in these new groups. 
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 Figure 2  |  Final classification tree. Information from the receiver operating characteristic analysis 
is combined into a decision tree showing the best algorithm for discriminating between the 
outcomes of interest. Sn, sensitivity; Sp, specificity. 
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Aft er adjusting for age, sex, prevalent car-
diovascular disease, hypertension, diabe-
tes, smoking, cholesterol, and albuminuria, 
the Chronic Kidney Disease Prognosis 
Consortium collaborators also found the 
turning point to be 75  ml / min per 1.73  m 2 . 
Th e traditional Cox regression analysis 
with post-estimation  C statistics for com-
parison of diff erent models is known to 
have a rather low ability to diff erentiate 
between models even if these are of sub-
stantially diff erent clinical importance. 
Other techniques have been suggested, 
and a few studies have used these new 
techniques on the current topic. Soveri  et 
al. analyzed a rather small but well-char-
acterized cohort of Swedish men ( n  =  2176) 
using the integrated discrimination 
improvement method. 10 Th ey found that 
the optimal cutoff  for predicting cardio-
vascular death was 92  ml / min per 1.73  m 2 , 
which is in accordance with the results of 
the study by Foley  et al. 6 
 Th e study by Foley  et al. , 6 as well as pre-
vious studies, clearly shows that kidney 
function and albuminuria are among the 
most important cardiovascular risk factors. 
Th is information has not yet been imple-
mented in clinical practice in an appropri-
ate way. Very few clinical guidelines on 
hypertension and cardiovascular disease 
mention eGFR and albuminuria as impor-
tant risk factors. 5 Furthermore, none of the 
commonly used risk equations has included 
these risk factors. An intensifi ed collabora-
tion between nephrologists and cardiolo-
gists is therefore highly recommended, in 
research, guideline development, and clin-
ical practice. As the very interesting article 
by Foley  et al. 6 indicates, the optimal cutoff  
values for prediction of mortality risk 
might not yet have been decided on. How-
ever, physicians should already now start 
to pay attention to kidney-related variables 
for risk stratifi cation. Chronic kidney dis-
ease is defi nitely a major cardiovascular 
risk factor that deserves full attention. 
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 20-HETE in acute kidney injury 
 Richard J.  Roman 1 ,  Talha  Akbulut 2 ,  Frank  Park 2 and  Kevin R.  Regner 2 
 Ischemia / reperfusion injury (IRI) is a common cause of acute kidney 
injury (AKI) that is associated with a patient mortality of up to 50 % . 
Currently there are not effective pharmacologic therapies for AKI. This 
Commentary highlights recent evidence indicating that 20-HETE plays 
an important role in IRI and that drugs that target this pathway have 
potential as therapeutic agents for AKI.  
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Ischemia / reperfusion injury (IRI) is a 
common cause of acute kidney injury 
(AKI) in a variety of clinical settings 
ranging from critical illness to renal 
transplantation. 1 AKI increases patient 
morbidity and is associated with patient 
mortality of up to 50 % . 1 Currently, there 
are no effective pharmacologic therapies 
for AKI in humans. Thus, there is a pro-
found need for new treatments for AKI. 
 Recent studies have reported that 
HET0016, a selective inhibitor of 20-
hydroxyeicosatetraenoic acid (20-HETE) 
synthesis, reduces infarct size in the brain 
and heart following IRI. 2 – 4 Interestingly, 
the benefi cial eff ect following IRI to the 
brain is independent of changes in cere-
bral blood fl ow, suggesting that the inhib-
itors of the synthesis of 20-HETE may 
have direct neuroprotective actions. 4 
Until recently, the role of CYP metabo-
lites of arachidonic acid in AKI had not 
been well characterized. The study 
by Hoff   et al. 5 (this issue) indicates that 
20-HETE may play a central role in renal 
IRI, and that agents that target the 
20-HETE pathway have the potential to 
minimize kidney injury. 
 Th e study by Hoff   et al. 5 is important 
because it provides the fi rst direct evi-
dence that renal 20-HETE levels increase 
during ischemia. Th e authors found that 
the release of 20-HETE increased four-
fold following ischemia in an isolated 
perfused kidney, and that this was attenu-
ated by 50 % by inclusion of 100  n m 
HET0016 in the perfusion solution. Simi-
larly, tissue levels of free 20-HETE 
